Preview

Antibiot Khimioter = Antibiotics and Chemotherapy

Advanced search

Studying the Effectiveness of Lariphan® in the Experimental Form Severe Acute Respiratory Syndrome

https://doi.org/10.24411/0235-2990-2019-100025

Abstract

Studies have been carried out to study the effectiveness of the high-molecular inducer of interferon Larifan® in relation to the experimental form of severe acute respiratory syndrome in Syrian hamsters. It is shown that Lariphan® is effective when applied in a preventive scheme, and the scheme of emergency prevention. The coefficient of therapeutic action for virological, hematological and biochemical parameters was 57.5 and 65.0%, respectively (ð<0.05 and ð<0.01).

About the Authors

S. Ya. Loginova
Federative State Central Research Institute No. 48 of the Ministry of Defense of Russia
Russian Federation


V. N. Shchukina
Federative State Central Research Institute No. 48 of the Ministry of Defense of Russia
Russian Federation


S. V. Borisevich
Federative State Central Research Institute No. 48 of the Ministry of Defense of Russia
Russian Federation


R. A. Hamitov
International Biotechnology Center «Generium»
Russian Federation


V. A. Maksimov
Federative State Central Research Institute No. 48 of the Ministry of Defense of Russia
Russian Federation


Review

For citations:


Loginova S.Ya., Shchukina V.N., Borisevich S.V., Hamitov R.A., Maksimov V.A. Studying the Effectiveness of Lariphan® in the Experimental Form Severe Acute Respiratory Syndrome. Antibiot Khimioter = Antibiotics and Chemotherapy. 2019;64(5-6):13-17. (In Russ.) https://doi.org/10.24411/0235-2990-2019-100025

Views: 4722


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 0235-2990 (Print)